These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 21561313)

  • 1. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
    Überall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
    Rauck RL; Tark M; Reyes E; Hayes TG; Bartkowiak AJ; Hassman D; Nalamachu S; Derrick R; Howell J
    Curr Med Res Opin; 2009 Dec; 25(12):2877-85. PubMed ID: 19814586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain.
    Nalamachu S; Hassman D; Wallace MS; Dumble S; Derrick R; Howell J
    Curr Med Res Opin; 2011 Mar; 27(3):519-30. PubMed ID: 21208151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
    Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
    Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
    Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
    Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
    J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
    Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain.
    Webster LR; Messina J; Xie F; Nalamachu S
    J Opioid Manag; 2011; 7(4):297-308. PubMed ID: 21957829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study.
    Lennernäs B; Frank-Lissbrant I; Lennernäs H; Kälkner KM; Derrick R; Howell J
    Palliat Med; 2010 Apr; 24(3):286-93. PubMed ID: 20015921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
    Portenoy RK; Taylor D; Messina J; Tremmel L
    Clin J Pain; 2006; 22(9):805-11. PubMed ID: 17057563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
    Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
    Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
    Jandhyala R; Fullarton JR; Bennett MI
    J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
    Nalamachu SR; Parikh N; Dillaha L; Rauck R
    J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Hashemi M; Zali A; Golmakani E; Delshad MH; Shadnoush M; Akbari ME
    Daru; 2021 Jun; 29(1):51-59. PubMed ID: 33475984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
    Slatkin NE; Xie F; Messina J; Segal TJ
    J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.